PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28231748-5 2017 In comparison with other cells, MCF-7 cells were more sensitive to AE treatment; AE enhanced the cytotoxicity of 9[Formula: see text][Formula: see text]g/ml tamoxifen by reducing EGFR, ER[Formula: see text], Ras, ERK, c-Myc, and mTOR protein expression and blocking PI3K and mTOR activation. Tamoxifen 157-166 epidermal growth factor receptor Homo sapiens 179-183 28955730-7 2017 Post-EMT cells exhibited (i) elevated expression of EGFR and IGF1R, which together with Src formed cytoplasmic complexes with ER-alpha; (ii) enhanced coupling of EGF, IGF-1 and estrogen to the activation of MAPKs; and (iii) reduced sensitivity to tamoxifen, an event reversed by administration of small molecule inhibitors against the receptors for TGF-beta, EGF, and IGF-1, as well as those against MAPKs. Tamoxifen 247-256 epidermal growth factor receptor Homo sapiens 52-56 27519631-0 2016 Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study. Tamoxifen 0-9 epidermal growth factor receptor Homo sapiens 84-88 27494858-0 2016 Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor. Tamoxifen 28-37 epidermal growth factor receptor Homo sapiens 106-138 27494858-5 2016 In the present study, we found that DCA sensitized MCF7 breast cancer cells to tamoxifen-induced cell death by decreasing epidermal growth factor receptor (EGFR) expression. Tamoxifen 79-88 epidermal growth factor receptor Homo sapiens 122-154 27494858-5 2016 In the present study, we found that DCA sensitized MCF7 breast cancer cells to tamoxifen-induced cell death by decreasing epidermal growth factor receptor (EGFR) expression. Tamoxifen 79-88 epidermal growth factor receptor Homo sapiens 156-160 27494858-7 2016 Furthermore, p38 mitogen-activated protein kinase played an important role in DCA/tamoxifen-induced EGFR degradation. Tamoxifen 82-91 epidermal growth factor receptor Homo sapiens 100-104 27083550-7 2016 We attempt to differentiate the effect that TAM has on purified Protein Kinase C (PKC) compared to that in an intact cell, suggesting that low micromolar concentrations of TAM indirectly inhibit PKC by inducing EGFR destruction and high micromolar concentrations of TAM inhibits PKC through a direct binding mechanism. Tamoxifen 44-47 epidermal growth factor receptor Homo sapiens 211-215 26884313-0 2016 Roles of the ER-alpha36-EGFR/HER2 positive regulatory loops in tamoxifen resistance. Tamoxifen 63-72 epidermal growth factor receptor Homo sapiens 24-28 26884313-3 2016 Extensive researches were conducted to understand the molecular mechanisms involved in tamoxifen resistance, and have revealed that multiple signaling molecules and pathways such as EGFR and HER2 are involved in tamoxifen resistance. Tamoxifen 87-96 epidermal growth factor receptor Homo sapiens 182-186 26884313-3 2016 Extensive researches were conducted to understand the molecular mechanisms involved in tamoxifen resistance, and have revealed that multiple signaling molecules and pathways such as EGFR and HER2 are involved in tamoxifen resistance. Tamoxifen 212-221 epidermal growth factor receptor Homo sapiens 182-186 26884313-6 2016 In this review, we will discuss the biological function and the possible underlying mechanisms of ER-alpha36 in tamoxifen resistance and specifically illustrate a novel cross-talk mechanism; positive regulatory loops between the ER-alpha36 and EGFR/HER2 in tamoxifen resistance. Tamoxifen 112-121 epidermal growth factor receptor Homo sapiens 244-248 26884313-6 2016 In this review, we will discuss the biological function and the possible underlying mechanisms of ER-alpha36 in tamoxifen resistance and specifically illustrate a novel cross-talk mechanism; positive regulatory loops between the ER-alpha36 and EGFR/HER2 in tamoxifen resistance. Tamoxifen 257-266 epidermal growth factor receptor Homo sapiens 244-248 27083550-7 2016 We attempt to differentiate the effect that TAM has on purified Protein Kinase C (PKC) compared to that in an intact cell, suggesting that low micromolar concentrations of TAM indirectly inhibit PKC by inducing EGFR destruction and high micromolar concentrations of TAM inhibits PKC through a direct binding mechanism. Tamoxifen 172-175 epidermal growth factor receptor Homo sapiens 211-215 27083550-7 2016 We attempt to differentiate the effect that TAM has on purified Protein Kinase C (PKC) compared to that in an intact cell, suggesting that low micromolar concentrations of TAM indirectly inhibit PKC by inducing EGFR destruction and high micromolar concentrations of TAM inhibits PKC through a direct binding mechanism. Tamoxifen 172-175 epidermal growth factor receptor Homo sapiens 211-215 25973295-5 2015 Here, we found that tamoxifen induced expression of ER-alpha36-EGFR/HER2 positive regulatory loops and tamoxifen resistant MCF7 cells (MCF7/TAM) expressed enhanced levels of the loops. Tamoxifen 20-29 epidermal growth factor receptor Homo sapiens 63-67 26581908-3 2016 Increased protein expression and signaling of epidermal growth factor receptor (EGFR) family is a possible mechanism involved in tamoxifen resistance. Tamoxifen 129-138 epidermal growth factor receptor Homo sapiens 46-78 26581908-3 2016 Increased protein expression and signaling of epidermal growth factor receptor (EGFR) family is a possible mechanism involved in tamoxifen resistance. Tamoxifen 129-138 epidermal growth factor receptor Homo sapiens 80-84 26803986-3 2016 Receptor tyrosine kinases (RTKs) such EGFR, ERBB2 and IGF1R are major mediators that can directly alter cellular response to the SERM, tamoxifen, but the mechanisms underlying increased expression of RTKs are not clear. Tamoxifen 135-144 epidermal growth factor receptor Homo sapiens 38-42 26697525-3 2015 EGFR expression is upregulated by direct binding of HOXB7 to the EGFR promoter, while HOXB7 functions as a cofactor with ERalpha to cause overexpression of multiple ER-target genes, including HER2, in tamoxifen resistant breast cancer cells. Tamoxifen 201-210 epidermal growth factor receptor Homo sapiens 0-4 26487496-0 2015 Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERalpha-positive breast cancer. Tamoxifen 27-36 epidermal growth factor receptor Homo sapiens 71-75 26487496-7 2015 Microarray of Rho GDIalpha KD cells indicated that activation of EGFR and ERalpha was associated with Tam treatment. Tamoxifen 102-105 epidermal growth factor receptor Homo sapiens 65-69 26487496-9 2015 Constitutive and Tam-induced phosphorylation of EGFR and ERK1/2 was blocked by the AR antagonist Enzalutamide, suggesting that AR-mediated EGFR activation was a mechanism of resistance in these cells. Tamoxifen 17-20 epidermal growth factor receptor Homo sapiens 48-52 26487496-9 2015 Constitutive and Tam-induced phosphorylation of EGFR and ERK1/2 was blocked by the AR antagonist Enzalutamide, suggesting that AR-mediated EGFR activation was a mechanism of resistance in these cells. Tamoxifen 17-20 epidermal growth factor receptor Homo sapiens 139-143 26487496-12 2015 We describe a novel model of AR-mediated Tam resistance through activation of EGFR signaling leading to ER activation in ERalpha-positive cells with low expression of Rho GDIalpha. Tamoxifen 41-44 epidermal growth factor receptor Homo sapiens 78-82 26238412-1 2015 The human epidermal growth factor receptor (HER) 4 is a relative of HER2 and has been associated to endocrine breast cancer and prediction of tamoxifen response. Tamoxifen 142-151 epidermal growth factor receptor Homo sapiens 10-42 26166014-0 2015 Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Tamoxifen 42-51 epidermal growth factor receptor Homo sapiens 23-27 26166014-2 2015 Here, we investigated the clinical value of epidermal growth factor receptor (EGFR) in tamoxifen-resistant (TamR) patients and the differential effect of EGFR inhibitors, neratinib and gefitinib, on TamR breast cancer cell model. Tamoxifen 87-96 epidermal growth factor receptor Homo sapiens 78-82 26166014-7 2015 Furthermore, we observed that EGFR expression was directly involved with poor prognosis of tamoxifen-treated breast cancer patients using the GSE1378 date set. Tamoxifen 91-100 epidermal growth factor receptor Homo sapiens 30-34 25882671-6 2015 In an effort to overcome the resistance, intensive research has been conducted to understand the underlying mechanisms; this has resulted in the identification of complex factors/pathways contributing to tamoxifen resistance, including modulations of the ERsignaling, upregulation of a set of growth factor receptor networks (HER2, EGFR, FGFR, and IGF1R), alterations of the PI3K-PTEN/AKT/mTOR pathway, and an elevation of the NF-kappaB signaling. Tamoxifen 204-213 epidermal growth factor receptor Homo sapiens 332-336 25973295-6 2015 Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops with the dual tyrosine kinase inhibitor Lapatinib or ER-alpha36 down-regulator Broussoflavonol B in tamoxifen resistant MCF7 cells restored tamoxifen sensitivity. Tamoxifen 165-174 epidermal growth factor receptor Homo sapiens 29-33 25973295-8 2015 Our results thus demonstrated that elevated expression of the ER-alpha36-EGFR/HER2 loops is one of the mechanisms by which ER-positive breast cancer cells escape tamoxifen therapy. Tamoxifen 162-171 epidermal growth factor receptor Homo sapiens 73-77 25973295-9 2015 Our results thus provided a rational to develop novel therapeutic approaches for tamoxifen resistant patients by targeting the ER-alpha36-EGFR/HER2 loops. Tamoxifen 81-90 epidermal growth factor receptor Homo sapiens 138-142 24091623-9 2013 In the HER1-3-negative subgroup, the hazard ratio (HR) for upfront exemestane vs tamoxifen at 2.75 years was 0.67 (95% confidence interval (CI), 0.52-0.87), in the HER1-3-positive subgroup, the HR was 1.15 (95% CI, 0.85-1.56). Tamoxifen 81-90 epidermal growth factor receptor Homo sapiens 7-11 25203051-5 2014 Here, we found that tamoxifen induced expression of ER-alpha36-EGFR/HER2 positive regulatory loops and tamoxifen resistant MCF7 cells (MCF7/TAM) expressed enhanced levels of the loops. Tamoxifen 20-29 epidermal growth factor receptor Homo sapiens 63-67 25203051-6 2014 Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops with the dual tyrosine kinase inhibitor Lapatinib or ER-alpha36 down-regulator Broussoflavonol B in tamoxifen resistant MCF7 cells restored tamoxifen sensitivity. Tamoxifen 165-174 epidermal growth factor receptor Homo sapiens 29-33 25203051-8 2014 Our results thus demonstrated that elevated expression of the ER-alpha36-EGFR/HER2 loops is one of the mechanisms by which ER-positive breast cancer cells escape tamoxifen therapy. Tamoxifen 162-171 epidermal growth factor receptor Homo sapiens 73-77 25203051-9 2014 Our results thus provided a rational to develop novel therapeutic approaches for tamoxifen resistant patients by targeting the ER-alpha36-EGFR/HER2 loops. Tamoxifen 81-90 epidermal growth factor receptor Homo sapiens 138-142 24916398-0 2014 Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition. Tamoxifen 23-32 epidermal growth factor receptor Homo sapiens 89-93 24414992-7 2014 Positive staining for EGFR and CD163+ macrophages were observed in 21 samples (43.8 %) and in 26 samples (54.2 %) respectively in tamoxifen resistance group, which were higher than that of tamoxifen sensitive group (P = 0.001 and P = 0.000279 respectively). Tamoxifen 130-139 epidermal growth factor receptor Homo sapiens 22-26 24414992-7 2014 Positive staining for EGFR and CD163+ macrophages were observed in 21 samples (43.8 %) and in 26 samples (54.2 %) respectively in tamoxifen resistance group, which were higher than that of tamoxifen sensitive group (P = 0.001 and P = 0.000279 respectively). Tamoxifen 189-198 epidermal growth factor receptor Homo sapiens 22-26 24758408-0 2014 Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. Tamoxifen 144-153 epidermal growth factor receptor Homo sapiens 0-32 25203051-0 2014 Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. Tamoxifen 74-83 epidermal growth factor receptor Homo sapiens 29-33 25203051-0 2014 Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. Tamoxifen 99-108 epidermal growth factor receptor Homo sapiens 29-33 24481325-8 2014 Importantly, TAM as well as G1 increased E2 production in breast CAFs via GPER/EGFR/ERK signaling when the substrate of E2, testosterone, was added to the medium. Tamoxifen 13-16 epidermal growth factor receptor Homo sapiens 79-83 24481325-10 2014 Accordingly, GPER-mediated CAF-dependent estrogenic effects on the tumor-associated stroma are conceivable, and CAF is likely to contribute to breast cancer progression, especially TAM resistance, via a positive feedback loop involving GPER/EGFR/ERK signaling and E2 production. Tamoxifen 181-184 epidermal growth factor receptor Homo sapiens 241-245 24091623-12 2013 CONCLUSION: In the 2.75 years prior to switching patients initially treated with tamoxifen to exemestane, a significant treatment-by-marker effect exists between AI/tamoxifen treatment and HER1-3 expression, suggesting HER expression could be used to select appropriate endocrine treatment at diagnosis to prevent or delay early relapses. Tamoxifen 81-90 epidermal growth factor receptor Homo sapiens 189-193 23609470-4 2013 Increased expression of EGFR and increased phosphorylation of HER3 were observed upon acquisition of tamoxifen resistance, and the extracellular activated kinase (ERK) signaling pathway was highly activated in the resistant cells. Tamoxifen 101-110 epidermal growth factor receptor Homo sapiens 24-28 23609470-5 2013 The EGFR inhibitor gefitinib and the ERK pathway inhibitor U0126 resulted in partial and preferential growth inhibition of tamoxifen-resistant cells. Tamoxifen 123-132 epidermal growth factor receptor Homo sapiens 4-8 22922893-0 2012 Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. Tamoxifen 149-158 epidermal growth factor receptor Homo sapiens 31-35 23273253-1 2012 BACKGROUND: G-protein-coupled estrogen receptor (GPER/GPR30) was reported to bind 17beta-estradiol (E2), tamoxifen, and ICI 182,780 (fulvestrant) and promotes activation of epidermal growth factor receptor (EGFR)-mediated signaling in breast, endometrial and thyroid cancer cells. Tamoxifen 105-114 epidermal growth factor receptor Homo sapiens 173-205 23273253-1 2012 BACKGROUND: G-protein-coupled estrogen receptor (GPER/GPR30) was reported to bind 17beta-estradiol (E2), tamoxifen, and ICI 182,780 (fulvestrant) and promotes activation of epidermal growth factor receptor (EGFR)-mediated signaling in breast, endometrial and thyroid cancer cells. Tamoxifen 105-114 epidermal growth factor receptor Homo sapiens 207-211 22808167-2 2012 Following tamoxifen withdrawal, tamoxifen-resistant MCF-7 cells conserved both drug resistance and an increased basal rate of proliferation in an oestrogen deprived environment, despite reduced epidermal growth-factor receptor expression and reduced sensitivity to gefitinib challenge. Tamoxifen 32-41 epidermal growth factor receptor Homo sapiens 194-226 23039365-14 2012 CONCLUSIONS: These data suggest an important role for CD44 in the context of tamoxifen-resistance where it may augment cellular response to erbB ligands and HA, factors that are reported to be present within the tumour microenvironment in vivo. Tamoxifen 77-86 epidermal growth factor receptor Homo sapiens 140-144 21935603-5 2012 Soluble factors produced by the fibroblastic cells protect the epithelial tumor cells from tamoxifen-induced cell death through a mechanism that involves EGFR and matrix metalloproteinases upstream of PI3K/AKT. Tamoxifen 91-100 epidermal growth factor receptor Homo sapiens 154-158 21690342-0 2012 The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Tamoxifen 59-68 epidermal growth factor receptor Homo sapiens 95-99 21690342-5 2012 Extended treatment of MCF-7 cells with tamoxifen resulted in progressively increasing levels of HOXB7 expression, along with EGFR and EGFR ligands. Tamoxifen 39-48 epidermal growth factor receptor Homo sapiens 125-129 21690342-5 2012 Extended treatment of MCF-7 cells with tamoxifen resulted in progressively increasing levels of HOXB7 expression, along with EGFR and EGFR ligands. Tamoxifen 39-48 epidermal growth factor receptor Homo sapiens 134-138 21273576-0 2011 Measuring IGF-1, ER-alpha and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer. Tamoxifen 58-67 epidermal growth factor receptor Homo sapiens 30-34 20446926-1 2011 The activation of the EGFR (epidermal growth factor receptor) signalling pathway is one of the key mechanisms underlying the development of resistance to tamoxifen in breast cancer patients. Tamoxifen 154-163 epidermal growth factor receptor Homo sapiens 22-26 20446926-1 2011 The activation of the EGFR (epidermal growth factor receptor) signalling pathway is one of the key mechanisms underlying the development of resistance to tamoxifen in breast cancer patients. Tamoxifen 154-163 epidermal growth factor receptor Homo sapiens 28-60 22042792-6 2011 Microarray expression analysis revealed downregulation of cell-cycle control and survival pathways and upregulation of erbB in response to BMS-754807 plus hormonal therapy, particularly tamoxifen. Tamoxifen 186-195 epidermal growth factor receptor Homo sapiens 119-123 20133149-2 2011 TAM can have both estrogen-antagonistic and estrogen-agonistic effects, and expression of growth factor receptors such as human epidermal growth factor receptor (HER)2 in breast cancer is associated with the development of TAM resistance. Tamoxifen 223-226 epidermal growth factor receptor Homo sapiens 128-160 21273576-1 2011 In vitro studies have suggested that tamoxifen resistance may be due to altered expression and downstream signalling of insulin-like growth factor-1 (IGF-1) receptor (IGF-1l), oestrogen receptor-alpha (ERalpha), epidermal growth factor receptor (EGFR) and HER-2. Tamoxifen 37-46 epidermal growth factor receptor Homo sapiens 212-244 21273576-1 2011 In vitro studies have suggested that tamoxifen resistance may be due to altered expression and downstream signalling of insulin-like growth factor-1 (IGF-1) receptor (IGF-1l), oestrogen receptor-alpha (ERalpha), epidermal growth factor receptor (EGFR) and HER-2. Tamoxifen 37-46 epidermal growth factor receptor Homo sapiens 246-250 21273576-9 2011 ERalpha inversely correlated with EGFR expression in the tamoxifen resistant group only. Tamoxifen 57-66 epidermal growth factor receptor Homo sapiens 34-38 20944147-0 2010 The Wilms" tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. Tamoxifen 145-154 epidermal growth factor receptor Homo sapiens 71-103 20944147-0 2010 The Wilms" tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. Tamoxifen 145-154 epidermal growth factor receptor Homo sapiens 105-109 20944147-12 2010 CONCLUSION: Our results indicated that WT1 is involved in expressional regulation of the EGFR family members and ER-alpha during development of acquired tamoxifen resistance. Tamoxifen 153-162 epidermal growth factor receptor Homo sapiens 89-93 19923318-6 2009 Initial clinical studies have suggested that EGFR inhibitors such as gefitinib may delay the development of resistance to endocrine therapy in patients with breast cancer when given concurrently with tamoxifen or an aromatase inhibitor. Tamoxifen 200-209 epidermal growth factor receptor Homo sapiens 45-49 19911269-10 2010 This data suggests the important role of GPR30/EGFR receptor signaling in the development of tamoxifen resistance. Tamoxifen 93-102 epidermal growth factor receptor Homo sapiens 47-51 20005069-8 2010 Additionally, EGFR and ERbeta expression was down-regulated in response to estrogen and EGF, respectively, but up-regulated in response to tamoxifen and genfitib, respectively. Tamoxifen 139-148 epidermal growth factor receptor Homo sapiens 14-18 19739079-1 2010 Estrogen receptor (ER)-positive acquired tamoxifen-resistant (TAM-R) MCF-7 breast cancer cell lines exhibit epidermal growth factor receptor (EGFR) expression/signaling and are growth-inhibited by gefitinib (IRESSA). Tamoxifen 41-50 epidermal growth factor receptor Homo sapiens 108-140 19739079-1 2010 Estrogen receptor (ER)-positive acquired tamoxifen-resistant (TAM-R) MCF-7 breast cancer cell lines exhibit epidermal growth factor receptor (EGFR) expression/signaling and are growth-inhibited by gefitinib (IRESSA). Tamoxifen 41-50 epidermal growth factor receptor Homo sapiens 142-146 19739079-9 2010 Acquired tamoxifen resistance appears in part mediated through EGFR signaling and can be blocked with gefitinib. Tamoxifen 9-18 epidermal growth factor receptor Homo sapiens 63-67 19288272-8 2010 Hyperactivation of EGFR/ERK is a feature of tamoxifen-resistant breast cancer cells, a principal driver of cell growth. Tamoxifen 44-53 epidermal growth factor receptor Homo sapiens 19-23 20847831-2 2010 As such, co-targeting ErbB1 and ErbB2 with lapatinib in combination with hormonal therapy is an attractive approach to enhance the efficacy of either tamoxifen or estrogen deprivation. Tamoxifen 150-159 epidermal growth factor receptor Homo sapiens 22-27 19749156-6 2009 Given that EGFR/HER2 overexpression is associated with tamoxifen resistance, our data may suggest that ligand-activated EGFR could contribute to the failure of tamoxifen therapy also by up-regulating GPR30, which in turn could facilitates the action of estrogen. Tamoxifen 55-64 epidermal growth factor receptor Homo sapiens 11-15 19749156-6 2009 Given that EGFR/HER2 overexpression is associated with tamoxifen resistance, our data may suggest that ligand-activated EGFR could contribute to the failure of tamoxifen therapy also by up-regulating GPR30, which in turn could facilitates the action of estrogen. Tamoxifen 55-64 epidermal growth factor receptor Homo sapiens 120-124 19749156-6 2009 Given that EGFR/HER2 overexpression is associated with tamoxifen resistance, our data may suggest that ligand-activated EGFR could contribute to the failure of tamoxifen therapy also by up-regulating GPR30, which in turn could facilitates the action of estrogen. Tamoxifen 160-169 epidermal growth factor receptor Homo sapiens 120-124 19749156-7 2009 In addition, important for resistance is the ability of tamoxifen to bind to and activate GPR30, the expression of which is up-regulated by EGFR activation. Tamoxifen 56-65 epidermal growth factor receptor Homo sapiens 140-144 19138696-0 2009 Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Tamoxifen 75-84 epidermal growth factor receptor Homo sapiens 67-71 19138696-6 2009 During the process of development of tamoxifen resistance this pathway is up-regulated with increased sensitivity to activate EGFR for cell growth and protection against apoptosis. Tamoxifen 37-46 epidermal growth factor receptor Homo sapiens 126-130 17902048-2 2008 Here, however, we show that in tamoxifen-resistant MCF-7 (Tam-R) breast cancer cells, that are highly dependent on epidermal growth factor receptor (EGFR) for growth, IRS-1 can interact with EGFR and be preferentially phosphorylated on tyrosine (Y) 896, a Grb2 binding site. Tamoxifen 31-40 epidermal growth factor receptor Homo sapiens 115-147 19285025-4 2009 Increased expression levels of HER1, HER2 and the estrogen receptor (ER)-AIB1 complex were found in tamoxifen-resistant cells. Tamoxifen 100-109 epidermal growth factor receptor Homo sapiens 31-35 19285025-5 2009 EGF stimulation and gefitinib inhibition experiments further demonstrated that HER1/HER2 signaling and AIB1 were involved in the proliferation of cells that had acquired Tam resistance. Tamoxifen 170-173 epidermal growth factor receptor Homo sapiens 79-83 19285025-8 2009 Thus, AIB1 may be a new therapeutic target, and the removal of AIB1 may decrease the crosstalk between ER and the HER1/HER2 pathway, resulting in the restoration of tamoxifen sensitivity in tamoxifen-resistant cells. Tamoxifen 165-174 epidermal growth factor receptor Homo sapiens 114-118 19285025-8 2009 Thus, AIB1 may be a new therapeutic target, and the removal of AIB1 may decrease the crosstalk between ER and the HER1/HER2 pathway, resulting in the restoration of tamoxifen sensitivity in tamoxifen-resistant cells. Tamoxifen 190-199 epidermal growth factor receptor Homo sapiens 114-118 17902048-2 2008 Here, however, we show that in tamoxifen-resistant MCF-7 (Tam-R) breast cancer cells, that are highly dependent on epidermal growth factor receptor (EGFR) for growth, IRS-1 can interact with EGFR and be preferentially phosphorylated on tyrosine (Y) 896, a Grb2 binding site. Tamoxifen 31-40 epidermal growth factor receptor Homo sapiens 149-153 17902048-2 2008 Here, however, we show that in tamoxifen-resistant MCF-7 (Tam-R) breast cancer cells, that are highly dependent on epidermal growth factor receptor (EGFR) for growth, IRS-1 can interact with EGFR and be preferentially phosphorylated on tyrosine (Y) 896, a Grb2 binding site. Tamoxifen 31-40 epidermal growth factor receptor Homo sapiens 191-195 17636398-0 2008 Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Tamoxifen 157-166 epidermal growth factor receptor Homo sapiens 0-32 18550772-9 2008 Increased EGFR and c-Src signaling is associated with tamoxifen resistance in ER+ breast cancer cells. Tamoxifen 54-63 epidermal growth factor receptor Homo sapiens 10-14 17636398-6 2008 In conclusion, both AIB1 and EGFR were associated to DDFS for breast cancer patients treated with two years of adjuvant tamoxifen; AIB1 with the development of early distant recurrences, indicating association between high AIB1 and resistance to tamoxifen during treatment, and EGFR with distant recurrences up to a follow up of five years. Tamoxifen 120-129 epidermal growth factor receptor Homo sapiens 29-33 17636398-6 2008 In conclusion, both AIB1 and EGFR were associated to DDFS for breast cancer patients treated with two years of adjuvant tamoxifen; AIB1 with the development of early distant recurrences, indicating association between high AIB1 and resistance to tamoxifen during treatment, and EGFR with distant recurrences up to a follow up of five years. Tamoxifen 246-255 epidermal growth factor receptor Homo sapiens 29-33 18396622-7 2007 (2) The general 3-year disease-free survival (DFS) rate of those treated with TAM was 92.7%; and the 3-year GFS rate of the subgroup of the TAM-treated patients with Her-1 overexpression was 91.2%, significantly lower than that of those without Her-2 overexpression (93.4%, P = 0.004). Tamoxifen 140-143 epidermal growth factor receptor Homo sapiens 166-171 18245484-3 2008 Epidermal growth factor receptor (EGFR) and HER2, which were barely detected in control estrogen-treated tumors, increased slightly with tamoxifen and were markedly increased when tumors became resistant. Tamoxifen 137-146 epidermal growth factor receptor Homo sapiens 0-32 18245484-3 2008 Epidermal growth factor receptor (EGFR) and HER2, which were barely detected in control estrogen-treated tumors, increased slightly with tamoxifen and were markedly increased when tumors became resistant. Tamoxifen 137-146 epidermal growth factor receptor Homo sapiens 34-38 18245484-5 2008 Phosphorylated levels of p42/44 and p38 mitogen-activated protein kinases (both downstream of EGFR/HER2) were increased in the tamoxifen-resistant tumors and were suppressed by gefitinib. Tamoxifen 127-136 epidermal growth factor receptor Homo sapiens 94-98 18245484-7 2008 Phosphorylated insulin-like growth factor-IR (IGF-IR), which can interact with both EGFR and membrane ER, was elevated in the tamoxifen-resistant tumors compared with the sensitive group. Tamoxifen 126-135 epidermal growth factor receptor Homo sapiens 84-88 18245484-10 2008 In conclusion, EGFR/HER2 may mediate tamoxifen resistance in ER-positive breast cancer despite continued suppression of ER genomic function by tamoxifen. Tamoxifen 37-46 epidermal growth factor receptor Homo sapiens 15-19 21048911-4 2008 Evidence suggests that additional markers may be introduced because of their potentially predictive value in adjuvant therapy: i) overexpression of epidermal growth factor receptor is likely inversely correlated to the sensitivity to estrogen antagonists; ii) presence of the GAB2 adaptor protein and of the ABCC3 and mdr-1 efflux pumps modulates taxane sensitivity in HER2-positive breast cancer; and iii) CYP2D6 genotyping should be a routine measure to avoid failure of tamox-ifen treatment. Tamoxifen 473-483 epidermal growth factor receptor Homo sapiens 148-180 17355262-9 2007 Expression of epidermal growth factor receptor was also inhibited by treatment with a high concentration of tamoxifen. Tamoxifen 108-117 epidermal growth factor receptor Homo sapiens 14-46 17634479-0 2007 Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. Tamoxifen 97-106 epidermal growth factor receptor Homo sapiens 28-60 17634479-2 2007 Here we assess the relationship between EGFR expression and tamoxifen response, with a new quantitative technology. Tamoxifen 60-69 epidermal growth factor receptor Homo sapiens 40-44 17634479-5 2007 RESULTS: In ER-positive patients, tamoxifen-treated patients with low EGFR expression (n = 113) showed a significant effect by 2 years of adjuvant tamoxifen (P = .01), in contrast to no treatment effect in the EGFR-high group (n = 73, P = .69). Tamoxifen 34-43 epidermal growth factor receptor Homo sapiens 70-74 17634479-5 2007 RESULTS: In ER-positive patients, tamoxifen-treated patients with low EGFR expression (n = 113) showed a significant effect by 2 years of adjuvant tamoxifen (P = .01), in contrast to no treatment effect in the EGFR-high group (n = 73, P = .69). Tamoxifen 34-43 epidermal growth factor receptor Homo sapiens 210-214 17634479-5 2007 RESULTS: In ER-positive patients, tamoxifen-treated patients with low EGFR expression (n = 113) showed a significant effect by 2 years of adjuvant tamoxifen (P = .01), in contrast to no treatment effect in the EGFR-high group (n = 73, P = .69). Tamoxifen 147-156 epidermal growth factor receptor Homo sapiens 70-74 17634479-7 2007 A significant beneficial effect of tamoxifen treatment was seen in the EGFR-low group (hazard ratio [HR] = 0.43 (95% CI, 0.22 to 0.84; P = .013) in contrast to no effect in the EGFR-high group (HR = 1.14; 95% CI, 0.59 to 2.22; P = .7) by using a Cox model. Tamoxifen 35-44 epidermal growth factor receptor Homo sapiens 71-75 17634479-7 2007 A significant beneficial effect of tamoxifen treatment was seen in the EGFR-low group (hazard ratio [HR] = 0.43 (95% CI, 0.22 to 0.84; P = .013) in contrast to no effect in the EGFR-high group (HR = 1.14; 95% CI, 0.59 to 2.22; P = .7) by using a Cox model. Tamoxifen 35-44 epidermal growth factor receptor Homo sapiens 177-181 17634479-8 2007 CONCLUSION: This study provides clinical evidence that confirms the basic work that has shown high EGFR can indicate resistance to tamoxifen. Tamoxifen 131-140 epidermal growth factor receptor Homo sapiens 99-103 17295235-8 2007 Further determination of the molecular markers showed that TAM and genistein combination synergistically induced BT-474 cell apoptosis in part by synergistic downregulation of the expression of survivin, one of the apoptotic effectors, and downregulation of EGFR, HER2, and ERalpha expression. Tamoxifen 59-62 epidermal growth factor receptor Homo sapiens 258-262 17234721-8 2007 In addition, genistein and TAM combination synergistically delayed the growth of breast tumor via decreased estrogen level and activity, and down-regulation of EGFR expression. Tamoxifen 27-30 epidermal growth factor receptor Homo sapiens 160-164 17363451-8 2007 In addition, inhibition of epidermal growth factor receptor (EGFR) opposed both Tam-induced ERK1/2 phosphorylation and cell death, which suggests that EGFR-associated mechanisms are involved in Tam-induced death. Tamoxifen 80-83 epidermal growth factor receptor Homo sapiens 27-59 17363451-8 2007 In addition, inhibition of epidermal growth factor receptor (EGFR) opposed both Tam-induced ERK1/2 phosphorylation and cell death, which suggests that EGFR-associated mechanisms are involved in Tam-induced death. Tamoxifen 80-83 epidermal growth factor receptor Homo sapiens 61-65 17363451-8 2007 In addition, inhibition of epidermal growth factor receptor (EGFR) opposed both Tam-induced ERK1/2 phosphorylation and cell death, which suggests that EGFR-associated mechanisms are involved in Tam-induced death. Tamoxifen 80-83 epidermal growth factor receptor Homo sapiens 151-155 17363451-8 2007 In addition, inhibition of epidermal growth factor receptor (EGFR) opposed both Tam-induced ERK1/2 phosphorylation and cell death, which suggests that EGFR-associated mechanisms are involved in Tam-induced death. Tamoxifen 194-197 epidermal growth factor receptor Homo sapiens 27-59 17363451-8 2007 In addition, inhibition of epidermal growth factor receptor (EGFR) opposed both Tam-induced ERK1/2 phosphorylation and cell death, which suggests that EGFR-associated mechanisms are involved in Tam-induced death. Tamoxifen 194-197 epidermal growth factor receptor Homo sapiens 61-65 17363451-8 2007 In addition, inhibition of epidermal growth factor receptor (EGFR) opposed both Tam-induced ERK1/2 phosphorylation and cell death, which suggests that EGFR-associated mechanisms are involved in Tam-induced death. Tamoxifen 194-197 epidermal growth factor receptor Homo sapiens 151-155 17912634-6 2007 In addition, ORR was significantly higher with letrozole than tamoxifen in the human epidermal growth factor receptor HER1/HER2+ subgroup (P=0.0004). Tamoxifen 62-71 epidermal growth factor receptor Homo sapiens 118-122 17332282-0 2007 Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients. Tamoxifen 92-101 epidermal growth factor receptor Homo sapiens 38-70 17283173-0 2007 Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Tamoxifen 25-34 epidermal growth factor receptor Homo sapiens 141-145 17283173-13 2007 Our results suggest that enhanced nongenomic function of ERalpha via cooperation with the EGFR pathway is one of the mechanisms responsible for acquired tamoxifen resistance. Tamoxifen 153-162 epidermal growth factor receptor Homo sapiens 90-94 17013895-1 2007 In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, with other chemotherapeutic drugs including estrogen receptor-beta (ER-beta) antagonist (tamoxifen) and topoisomerase II inhibitor (etoposide) on some metastatic prostate cancer (PC) cell lines. Tamoxifen 300-309 epidermal growth factor receptor Homo sapiens 133-165 17013895-1 2007 In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, with other chemotherapeutic drugs including estrogen receptor-beta (ER-beta) antagonist (tamoxifen) and topoisomerase II inhibitor (etoposide) on some metastatic prostate cancer (PC) cell lines. Tamoxifen 300-309 epidermal growth factor receptor Homo sapiens 167-171 17048231-2 2006 METHODS: Pretreatment serum EGFR levels were quantified by using an enzyme-linked immunoadsorbent assay in a Phase III first-line trial of letrozole and tamoxifen and were correlated with patient outcomes. Tamoxifen 153-162 epidermal growth factor receptor Homo sapiens 28-32 17259562-5 2006 Here, we describe both non-genomic and genomic mechanisms of resistance to the selective EGFR tyrosine kinase inhibitor gefitinib (IRESSA), which we have identified initially in an EGFR-positive tamoxifen-resistant MCF-7 breast cancer cell line, but more recently in other EGFR-positive cancer types. Tamoxifen 195-204 epidermal growth factor receptor Homo sapiens 89-93 17259562-5 2006 Here, we describe both non-genomic and genomic mechanisms of resistance to the selective EGFR tyrosine kinase inhibitor gefitinib (IRESSA), which we have identified initially in an EGFR-positive tamoxifen-resistant MCF-7 breast cancer cell line, but more recently in other EGFR-positive cancer types. Tamoxifen 195-204 epidermal growth factor receptor Homo sapiens 181-185 17259562-5 2006 Here, we describe both non-genomic and genomic mechanisms of resistance to the selective EGFR tyrosine kinase inhibitor gefitinib (IRESSA), which we have identified initially in an EGFR-positive tamoxifen-resistant MCF-7 breast cancer cell line, but more recently in other EGFR-positive cancer types. Tamoxifen 195-204 epidermal growth factor receptor Homo sapiens 181-185 16261397-0 2006 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Tamoxifen 80-89 epidermal growth factor receptor Homo sapiens 45-49 16849545-8 2006 Importantly, Cas-dependent protection from the antiproliferative effects of tamoxifen was reversed by the expression of dominant inhibitory variants of these substrates (Y845F EGFR and COOH-terminally truncated STAT5b). Tamoxifen 76-85 epidermal growth factor receptor Homo sapiens 176-180 16849545-9 2006 Based on these findings, we suggest that the Cas/c-Src/EGFR/STAT5 signaling axis is a major regulator of tamoxifen-resistant breast cancer cell growth and survival. Tamoxifen 105-114 epidermal growth factor receptor Homo sapiens 55-59 16333527-3 2006 We have previously demonstrated that, upon acquisition of tamoxifen resistance, MCF7 cells display increased epidermal growth factor receptor (EGFR) activation and a more aggressive phenotype in vitro. Tamoxifen 58-67 epidermal growth factor receptor Homo sapiens 109-141 16333527-3 2006 We have previously demonstrated that, upon acquisition of tamoxifen resistance, MCF7 cells display increased epidermal growth factor receptor (EGFR) activation and a more aggressive phenotype in vitro. Tamoxifen 58-67 epidermal growth factor receptor Homo sapiens 143-147 16497822-0 2006 Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Tamoxifen 22-31 epidermal growth factor receptor Homo sapiens 127-139 16849545-0 2006 Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Tamoxifen 66-75 epidermal growth factor receptor Homo sapiens 137-169 16831274-0 2006 [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells]. Tamoxifen 70-79 epidermal growth factor receptor Homo sapiens 16-48 16831274-14 2006 CONCLUSION: In endocrine therapy, TAM resistant breast cancer cells are likely to be generated by the activation of EGFR signaling pathway after long-term TAM treatment, and EGFR inhibitors might increase the therapeutic effects in breast cancer treatment. Tamoxifen 34-37 epidermal growth factor receptor Homo sapiens 116-120 16831274-14 2006 CONCLUSION: In endocrine therapy, TAM resistant breast cancer cells are likely to be generated by the activation of EGFR signaling pathway after long-term TAM treatment, and EGFR inhibitors might increase the therapeutic effects in breast cancer treatment. Tamoxifen 155-158 epidermal growth factor receptor Homo sapiens 116-120 16831274-14 2006 CONCLUSION: In endocrine therapy, TAM resistant breast cancer cells are likely to be generated by the activation of EGFR signaling pathway after long-term TAM treatment, and EGFR inhibitors might increase the therapeutic effects in breast cancer treatment. Tamoxifen 155-158 epidermal growth factor receptor Homo sapiens 174-178 16455819-5 2006 In this report we now show that overexpression of EGFR or activated AKT-2 in MCF-7 cells leads to phosphorylation of Ser167 in the AF-1 domain of ERalpha, enhanced ER-amplified in breast cancer 1 (ER:AIB1) interaction in the presence of tamoxifen, and resistance to tamoxifen. Tamoxifen 237-246 epidermal growth factor receptor Homo sapiens 50-54 16455819-5 2006 In this report we now show that overexpression of EGFR or activated AKT-2 in MCF-7 cells leads to phosphorylation of Ser167 in the AF-1 domain of ERalpha, enhanced ER-amplified in breast cancer 1 (ER:AIB1) interaction in the presence of tamoxifen, and resistance to tamoxifen. Tamoxifen 266-275 epidermal growth factor receptor Homo sapiens 50-54 16261397-1 2006 We have previously demonstrated that oestrogen receptor alpha (ERalpha) modulates epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK) signalling efficiency in a tamoxifen-resistant MCF-7 breast cancer cell line (Tam-R). Tamoxifen 189-198 epidermal growth factor receptor Homo sapiens 82-114 16261397-1 2006 We have previously demonstrated that oestrogen receptor alpha (ERalpha) modulates epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK) signalling efficiency in a tamoxifen-resistant MCF-7 breast cancer cell line (Tam-R). Tamoxifen 189-198 epidermal growth factor receptor Homo sapiens 116-120 16467116-10 2006 Furthermore, proline-, glutamic acid-, leucine-rich protein 1, an ER coactivator involved in both genomic and nongenomic signaling pathways, is activated by epidermal growth factor receptor and plays a prominent role in resistance to tamoxifen. Tamoxifen 234-243 epidermal growth factor receptor Homo sapiens 157-189 16080193-9 2006 These results suggest that homotypic adhesion in tamoxifen-resistant breast cancer cells is dysfunctional due to EGFR-driven modulation of the phosphorylation status of beta-catenin and may contribute to an enhanced aggressive phenotype and transition towards a mesenchymal phenotype in vitro. Tamoxifen 49-58 epidermal growth factor receptor Homo sapiens 113-117 16113104-2 2005 Our recent in vitro studies also suggest that EGFR signalling productively cross-talks with insulin-like growth factor receptor (IGF-1R) and, where present, activates ER on key AF-1 serine residues to facilitate acquired tamoxifen-resistant growth. Tamoxifen 221-230 epidermal growth factor receptor Homo sapiens 46-50 16037379-2 2005 In the present study, we have examined whether EGFR/IGF-IR cross-talk exists in EGFR-positive tamoxifen-resistant variants of MCF-7 (Tam-R) and T47D (T47D-R) breast cancer cell lines. Tamoxifen 94-103 epidermal growth factor receptor Homo sapiens 47-51 16037379-2 2005 In the present study, we have examined whether EGFR/IGF-IR cross-talk exists in EGFR-positive tamoxifen-resistant variants of MCF-7 (Tam-R) and T47D (T47D-R) breast cancer cell lines. Tamoxifen 94-103 epidermal growth factor receptor Homo sapiens 80-84 16037379-11 2005 This cross-talk between IGF-IR and EGFR is not unique to Tam-R cells because this mechanism is also active in a tamoxifen-resistant T47D-R cell line. Tamoxifen 112-121 epidermal growth factor receptor Homo sapiens 35-39 16145046-2 2005 It has also been reported that tamoxifen may be less effective in tumors that overexpress either HER-2 or HER-1 (epidermal growth factor receptor) and that signaling through these receptors reduces PR expression in experimental models. Tamoxifen 31-40 epidermal growth factor receptor Homo sapiens 106-111 16145046-2 2005 It has also been reported that tamoxifen may be less effective in tumors that overexpress either HER-2 or HER-1 (epidermal growth factor receptor) and that signaling through these receptors reduces PR expression in experimental models. Tamoxifen 31-40 epidermal growth factor receptor Homo sapiens 113-145 16145046-9 2005 Among all tamoxifen-treated women, recurrence was higher among women with HER-1-expressing tumors than with HER-1-negative tumors (HR = 1.9, 95% CI = 1.0 to 3.5; P = .05); a stronger association between worse DFS and HER-2 overexpression was observed (HR = 2.3, 95% CI = 1.2 to 4.3; P = .006). Tamoxifen 10-19 epidermal growth factor receptor Homo sapiens 74-79 16145046-9 2005 Among all tamoxifen-treated women, recurrence was higher among women with HER-1-expressing tumors than with HER-1-negative tumors (HR = 1.9, 95% CI = 1.0 to 3.5; P = .05); a stronger association between worse DFS and HER-2 overexpression was observed (HR = 2.3, 95% CI = 1.2 to 4.3; P = .006). Tamoxifen 10-19 epidermal growth factor receptor Homo sapiens 108-113 15970523-6 2005 In addition, preclinical and clinical findings support the use of EGFR TKIs in specific subgroups of breast cancer patients, such as estrogen receptor positive (ER+), tamoxifen resistant patients. Tamoxifen 167-176 epidermal growth factor receptor Homo sapiens 66-70 16000581-3 2005 We now show that both HER1-3 and PR status predicts for early relapse in estrogen receptor (ER)-positive tamoxifen-treated breast cancer patients. Tamoxifen 105-114 epidermal growth factor receptor Homo sapiens 22-26 16000581-7 2005 RESULTS: HER1-3 (but not HER4) overexpression predicted for early relapse on tamoxifen (P = 0.0060). Tamoxifen 77-86 epidermal growth factor receptor Homo sapiens 9-15 16000581-9 2005 HER1-3-positive and/or PR-negative patients combined as a "high-risk" group were significantly more likely to relapse on tamoxifen in univariate (P < 0.0001) and Cox"s multivariate analysis (P = 0.0069). Tamoxifen 121-130 epidermal growth factor receptor Homo sapiens 0-4 16000581-11 2005 CONCLUSIONS: We show that HER1-3 and PR status can identify time-dependent de novo tamoxifen resistance with risk declining markedly after 3 years of tamoxifen treatment. Tamoxifen 83-92 epidermal growth factor receptor Homo sapiens 26-30 16000581-11 2005 CONCLUSIONS: We show that HER1-3 and PR status can identify time-dependent de novo tamoxifen resistance with risk declining markedly after 3 years of tamoxifen treatment. Tamoxifen 150-159 epidermal growth factor receptor Homo sapiens 26-30 16113090-1 2005 Studies of cell models and profiling of clinical breast cancer material to reveal the mechanisms of resistance to anti-oestrogen therapy, and to tamoxifen in particular, have reported that this phenomenon can be associated with increased expression and signalling through erbB Type 1 growth factor receptors, notably the epidermal growth factor receptor (EGFR) and HER2. Tamoxifen 145-154 epidermal growth factor receptor Homo sapiens 321-353 16113090-1 2005 Studies of cell models and profiling of clinical breast cancer material to reveal the mechanisms of resistance to anti-oestrogen therapy, and to tamoxifen in particular, have reported that this phenomenon can be associated with increased expression and signalling through erbB Type 1 growth factor receptors, notably the epidermal growth factor receptor (EGFR) and HER2. Tamoxifen 145-154 epidermal growth factor receptor Homo sapiens 355-359 16273359-6 2005 Compelling experimental and clinical evidence suggest that the epidermal growth factor/HER2/neu receptor (EGFR/HER2) pathway might play a distinct role in endocrine resistance, and especially in resistance to selective estrogen receptor modulators (SERMs) such as tamoxifen. Tamoxifen 264-273 epidermal growth factor receptor Homo sapiens 106-110 16037379-0 2005 Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Tamoxifen 51-60 epidermal growth factor receptor Homo sapiens 111-143 16202921-12 2005 Based on these results, it was hypothesized that EGF receptor signaling could differentially be affected by estrogen, tamoxifen, raloxifene, and ICI182780 because these four compounds differentially regulate the EGF receptor ligand amphiregulin. Tamoxifen 118-127 epidermal growth factor receptor Homo sapiens 49-61 16202921-12 2005 Based on these results, it was hypothesized that EGF receptor signaling could differentially be affected by estrogen, tamoxifen, raloxifene, and ICI182780 because these four compounds differentially regulate the EGF receptor ligand amphiregulin. Tamoxifen 118-127 epidermal growth factor receptor Homo sapiens 212-224 16113104-3 2005 This paper presents our immunohistochemical evidence that EGFR/HER2 signalling (i.e. transforming growth factor (TGF)alpha, EGFR and HER2 expression; phosphorylation of EGFR, HER2 and ERK1/2 MAP kinase) is also prominent in clinical de novo resistant and modestly increased in acquired tamoxifen-resistant states, suggesting that anti-EGFR/HER2 strategies may prove valuable treatments. Tamoxifen 286-295 epidermal growth factor receptor Homo sapiens 58-62 15355892-3 2004 The present study examined whether HER-2 gene amplification or HER-1 expression predicted response to tamoxifen. Tamoxifen 102-111 epidermal growth factor receptor Homo sapiens 63-68 15613453-3 2004 Continuous exposure of EGFR-positive MCF-7-derived tamoxifen resistant breast cancer cells (TAM-R) to 1 microM gefitinib resulted in a sustained growth inhibition (90%) for 4 months before the surviving cells resumed proliferation. Tamoxifen 51-60 epidermal growth factor receptor Homo sapiens 23-27 15665275-0 2005 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Tamoxifen 70-79 epidermal growth factor receptor Homo sapiens 9-14 15665275-4 2005 ErbB2 or ErbB1 overexpression can abrogate tamoxifen sensitivity in breast cancer lines through both reduction in p27 levels and inhibition of its function. Tamoxifen 43-52 epidermal growth factor receptor Homo sapiens 9-14 15665275-5 2005 Here we show that the dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), can restore tamoxifen sensitivity in ER-positive, tamoxifen-resistant breast cancer models. Tamoxifen 84-93 epidermal growth factor receptor Homo sapiens 27-32 15665275-5 2005 Here we show that the dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), can restore tamoxifen sensitivity in ER-positive, tamoxifen-resistant breast cancer models. Tamoxifen 122-131 epidermal growth factor receptor Homo sapiens 27-32 15355892-12 2004 CONCLUSION: Patients with HER-2 amplification and HER-1 expression had lower ER levels and were modestly less responsive to tamoxifen, suggesting that molecular events in addition to those involving the ErbB receptors are important in determining the endocrine-resistant phenotype. Tamoxifen 124-133 epidermal growth factor receptor Homo sapiens 50-55 15199112-6 2004 Molecular cross-talk between the ER and HER2 pathways was increased in the MCF-7/HER-2 cells compared with MCF-7 cells, with cross-phosphorylation and activation of both the ER and the EGFR/HER2 receptors, the signaling molecules AKT and ERK 1,2 mitogen-activated protein kinase (MAPK), and AIB1 itself with both estrogen and tamoxifen treatment. Tamoxifen 326-335 epidermal growth factor receptor Homo sapiens 185-189 15387370-3 2004 Using a previously established in vitro cell model of tamoxifen resistance in MCF7 cells, shown to display autocrine epidermal growth factor receptor (EGFR) signalling, we assessed how resistance might modulate their metastatic phenotype in vitro, as metastatic disease is the single most important factor affecting the mortality of cancer patients. Tamoxifen 54-63 epidermal growth factor receptor Homo sapiens 117-149 15015704-5 2004 The results indicate that the distinct mechanisms by which tamoxifen and letrozole inhibit ER signaling may produce quite marked differences in clinical and biomarker outcomes in the subset of tumors that coexpress HER1 and/or HER2 with ER, favoring estrogen-deprivation therapy. Tamoxifen 59-68 epidermal growth factor receptor Homo sapiens 215-219 15387370-3 2004 Using a previously established in vitro cell model of tamoxifen resistance in MCF7 cells, shown to display autocrine epidermal growth factor receptor (EGFR) signalling, we assessed how resistance might modulate their metastatic phenotype in vitro, as metastatic disease is the single most important factor affecting the mortality of cancer patients. Tamoxifen 54-63 epidermal growth factor receptor Homo sapiens 151-155 15387370-9 2004 Inhibition of EGFR signalling by gefitinib significantly inhibited cell motility and invasion thus suggesting a role for the EGF receptor in the aggressive phenotype of tamoxifen-resistant breast cancer cells. Tamoxifen 169-178 epidermal growth factor receptor Homo sapiens 14-18 15387370-9 2004 Inhibition of EGFR signalling by gefitinib significantly inhibited cell motility and invasion thus suggesting a role for the EGF receptor in the aggressive phenotype of tamoxifen-resistant breast cancer cells. Tamoxifen 169-178 epidermal growth factor receptor Homo sapiens 125-137 14623525-7 2003 This suggests that HER1/2 predicts primary tamoxifen resistance and relative sensitivity to potent estrogen deprivation, perhaps because HER1/2 signaling promotes the partial agonist effects of tamoxifen. Tamoxifen 43-52 epidermal growth factor receptor Homo sapiens 19-23 12960029-7 2003 EGFR induction occurred during TAM response, as measured by immunocytochemistry and Western blotting, with EGFR-positive, highly proliferative resistant growth subsequently emerging. Tamoxifen 31-34 epidermal growth factor receptor Homo sapiens 0-4 14559846-10 2003 The molecular basis for this advantage appears complex but includes possible tamoxifen agonist effects on the cell cycle in both HER1/2+ and HER1/2- tumors. Tamoxifen 77-86 epidermal growth factor receptor Homo sapiens 129-135 14559846-10 2003 The molecular basis for this advantage appears complex but includes possible tamoxifen agonist effects on the cell cycle in both HER1/2+ and HER1/2- tumors. Tamoxifen 77-86 epidermal growth factor receptor Homo sapiens 129-133 14531500-0 2003 Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Tamoxifen 67-76 epidermal growth factor receptor Homo sapiens 46-50 14623525-7 2003 This suggests that HER1/2 predicts primary tamoxifen resistance and relative sensitivity to potent estrogen deprivation, perhaps because HER1/2 signaling promotes the partial agonist effects of tamoxifen. Tamoxifen 194-203 epidermal growth factor receptor Homo sapiens 19-23 14623525-7 2003 This suggests that HER1/2 predicts primary tamoxifen resistance and relative sensitivity to potent estrogen deprivation, perhaps because HER1/2 signaling promotes the partial agonist effects of tamoxifen. Tamoxifen 194-203 epidermal growth factor receptor Homo sapiens 137-141 14649542-11 2003 We conclude that the capacity of Q and TAM to increase apoptosis in EGFR-activated cells makes these compounds possible chemopreventive drugs in subjects at risk of developing laryngeal cancer. Tamoxifen 39-42 epidermal growth factor receptor Homo sapiens 68-72 12586780-0 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Tamoxifen 123-132 epidermal growth factor receptor Homo sapiens 19-51 11778232-5 2000 The growth inhibitory effect on the 2 cell lines could be augmented and accompanied by a decrease in EGFR mRNA level after combined treatment with IC50 dose of tamoxifen and 10(-10)-10(-9) mol/L vitamin D3. Tamoxifen 160-169 epidermal growth factor receptor Homo sapiens 101-105 11559718-1 2001 PURPOSE: Expression of ErbB-1 and ErbB-2 (epidermal growth factor receptor and HER2/neu) in breast cancer may cause tamoxifen resistance, but not all studies concur. Tamoxifen 116-125 epidermal growth factor receptor Homo sapiens 23-29 11559718-1 2001 PURPOSE: Expression of ErbB-1 and ErbB-2 (epidermal growth factor receptor and HER2/neu) in breast cancer may cause tamoxifen resistance, but not all studies concur. Tamoxifen 116-125 epidermal growth factor receptor Homo sapiens 42-74 11559718-9 2001 Differences in response rates between letrozole and tamoxifen were most marked for tumors that were positive for ErbB-1 and/or ErbB-2 and ER (88% v 21%, P =.0004). Tamoxifen 52-61 epidermal growth factor receptor Homo sapiens 113-119 11454885-0 2001 Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. Tamoxifen 106-115 epidermal growth factor receptor Homo sapiens 9-41 11454885-2 2001 HER2, epidermal growth factor receptor (EGFR), and p53 have all been suggested as possible markers of tamoxifen resistance. Tamoxifen 102-111 epidermal growth factor receptor Homo sapiens 6-38 11454885-2 2001 HER2, epidermal growth factor receptor (EGFR), and p53 have all been suggested as possible markers of tamoxifen resistance. Tamoxifen 102-111 epidermal growth factor receptor Homo sapiens 40-44 11454885-3 2001 The aim of this study was to investigate interactions between adjuvant treatment with tamoxifen and the content of EGFR, HER2, and p53 in steroid receptor-positive patients. Tamoxifen 86-95 epidermal growth factor receptor Homo sapiens 115-119 11454885-9 2001 Patients with steroid receptor-positive tumors and positive immunohistochemical staining for HER2, EGFR or p53 benefited from treatment with tamoxifen for 1 year, although the latter variable contained independent prognostic information by itself. Tamoxifen 141-150 epidermal growth factor receptor Homo sapiens 99-103 11916224-5 2001 Resistance to tamoxifen is associated with up-regulation of the EGFR-TK pathway and mitogen-activated protein kinase activity is substantially increased in tamoxifen-resistant MCF-7 cells. Tamoxifen 14-23 epidermal growth factor receptor Homo sapiens 64-68 11916224-5 2001 Resistance to tamoxifen is associated with up-regulation of the EGFR-TK pathway and mitogen-activated protein kinase activity is substantially increased in tamoxifen-resistant MCF-7 cells. Tamoxifen 156-165 epidermal growth factor receptor Homo sapiens 64-68 10601607-0 2000 Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice. Tamoxifen 72-81 epidermal growth factor receptor Homo sapiens 36-68 34407787-2 2021 We aimed to investigate the role of the EGFR and Src-mediated STAT3 signalling pathway in tamoxifen-resistant breast cancer cells. Tamoxifen 90-99 epidermal growth factor receptor Homo sapiens 40-44 10542936-0 1999 Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifen-treated endometrium. Tamoxifen 80-89 epidermal growth factor receptor Homo sapiens 44-76 10542936-5 1999 No EGFR overexpression was found in the glandular cells of the tamoxifen-treated premenopausal patients, but expression of EGFR was high in glandular cells of the tamoxifen-treated postmenopausal patients associated with a high Ki-67 index. Tamoxifen 163-172 epidermal growth factor receptor Homo sapiens 123-127 10542936-7 1999 This estrogenic effect of tamoxifen may be associated with an EGFR autocrine system. Tamoxifen 26-35 epidermal growth factor receptor Homo sapiens 62-66 1616857-0 1992 Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Tamoxifen 103-112 epidermal growth factor receptor Homo sapiens 11-43 9815855-0 1997 Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Tamoxifen 85-94 epidermal growth factor receptor Homo sapiens 14-46 9815855-10 1997 The inverse relationship between EGFR and estrogen receptor was maintained at relapse on tamoxifen. Tamoxifen 89-98 epidermal growth factor receptor Homo sapiens 33-37 2285594-0 1990 Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. Tamoxifen 120-129 epidermal growth factor receptor Homo sapiens 0-32 2285594-0 1990 Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. Tamoxifen 120-129 epidermal growth factor receptor Homo sapiens 34-38 34407787-16 2021 CONCLUSIONS: The EGFR and Src-mediated STAT3 signalling pathway is activated in TamR cells, and inhibition of STAT3 may be a potential target in tamoxifen-resistant breast cancer. Tamoxifen 145-154 epidermal growth factor receptor Homo sapiens 17-21 2463445-7 1989 Including patients whose disease remained stable for more than 6 months with the responders, however, EGFR status was a better predictor of response to tamoxifen; 15 of 37 EGFR-negative patients and 5 of 35 EGFR-positive patients responded (p less than 0.01), compared with 13 of 32 ER-positive and 7 of 40 ER-negative patients (not significant). Tamoxifen 152-161 epidermal growth factor receptor Homo sapiens 102-106 35445730-0 2022 EGFR inhibition reverses epithelial-mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. Tamoxifen 74-83 epidermal growth factor receptor Homo sapiens 0-4 35445730-6 2022 In addition, it was observed that the inhibition of epidermal growth factor receptor (EGFR) reversed the EMT phenotype in tamoxifen-resistant MCF7 (MCF-7/TR) cells via the downregulation of Snail and Twist. Tamoxifen 122-131 epidermal growth factor receptor Homo sapiens 52-84 35445730-6 2022 In addition, it was observed that the inhibition of epidermal growth factor receptor (EGFR) reversed the EMT phenotype in tamoxifen-resistant MCF7 (MCF-7/TR) cells via the downregulation of Snail and Twist. Tamoxifen 122-131 epidermal growth factor receptor Homo sapiens 86-90 35445730-7 2022 Notably, the EGFR inhibitor, gefitinib, decreased tamoxifen resistance, migration and invasion through the inhibition of Snail and Twist. Tamoxifen 50-59 epidermal growth factor receptor Homo sapiens 13-17 35445730-8 2022 On the whole, the results of the present study suggest that EGFR may be a promising therapeutic target for tamoxifen-resistant breast cancer. Tamoxifen 107-116 epidermal growth factor receptor Homo sapiens 60-64 35559420-14 2022 CONCLUSION: Circ_0001946 absorbs miR-671-5p to target EGFR to promote the growth and malignant invasion of drug-resistant BC cells, thereby increasing the resistance to tamoxifen. Tamoxifen 169-178 epidermal growth factor receptor Homo sapiens 54-58 35337112-8 2022 Analysis of the protein expression profile showed that while being cytotoxic, tamoxifen elevated the levels of different tumor growth-promoting factors (e.g., Bcl-XL, Survivin, EGFR, Cathepsins, chemokines). Tamoxifen 78-87 epidermal growth factor receptor Homo sapiens 177-181 2576295-14 1989 Including patients whose disease remained stable for more than 6 months with the responders, however, EGFR status was a better predictor of response to tamoxifen; 15 of 37 EGFR- patients and 5 of 35 EGFR+ patients responded (P less than 0.01). Tamoxifen 152-161 epidermal growth factor receptor Homo sapiens 102-106 2576295-14 1989 Including patients whose disease remained stable for more than 6 months with the responders, however, EGFR status was a better predictor of response to tamoxifen; 15 of 37 EGFR- patients and 5 of 35 EGFR+ patients responded (P less than 0.01). Tamoxifen 152-161 epidermal growth factor receptor Homo sapiens 172-176 2576295-14 1989 Including patients whose disease remained stable for more than 6 months with the responders, however, EGFR status was a better predictor of response to tamoxifen; 15 of 37 EGFR- patients and 5 of 35 EGFR+ patients responded (P less than 0.01). Tamoxifen 152-161 epidermal growth factor receptor Homo sapiens 172-176 33691171-7 2021 EGFR expression was negatively associated with drug sensitivity of Pipamperone, Tamoxifen, Bafetinib and positively related to drug sensitivity of Dasatinib and Staurosporine. Tamoxifen 80-89 epidermal growth factor receptor Homo sapiens 0-4 3242819-7 1988 Tamoxifen suppressed MCF-7 cell growth, and spot hybridization of the RNA of MCF-7 cells revealed that RNA activities of estrogen and EGF receptor genes and myc, ras, and fos oncogenes were suppressed by tamoxifen. Tamoxifen 0-9 epidermal growth factor receptor Homo sapiens 134-146 3242819-7 1988 Tamoxifen suppressed MCF-7 cell growth, and spot hybridization of the RNA of MCF-7 cells revealed that RNA activities of estrogen and EGF receptor genes and myc, ras, and fos oncogenes were suppressed by tamoxifen. Tamoxifen 204-213 epidermal growth factor receptor Homo sapiens 134-146 34058187-0 2021 Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor alpha and the EGFR/HER2 signaling pathway. Tamoxifen 0-9 epidermal growth factor receptor Homo sapiens 146-150 34006822-4 2021 In turn, M2-like TAMs activate breast cancer cells through EGFR/PI3K/Akt signaling, providing feedback to upregulate SGLT1 and promote tamoxifen resistance and accelerate tumor growth in vitro and in vivo. Tamoxifen 135-144 epidermal growth factor receptor Homo sapiens 59-63 33046784-8 2020 ERRFI1 is an endogenous inhibitor of ERBB-signaling, which is a known driver of tamoxifen-resistance. Tamoxifen 80-89 epidermal growth factor receptor Homo sapiens 37-41 33508166-3 2021 Two commonly reported biomarkers of tamoxifen resistance are decreased expression of insulin-like growth factor 1 receptor (IGF-1R) and increased expression of epidermal growth factor receptor (EGFR). Tamoxifen 36-45 epidermal growth factor receptor Homo sapiens 160-192 33508166-3 2021 Two commonly reported biomarkers of tamoxifen resistance are decreased expression of insulin-like growth factor 1 receptor (IGF-1R) and increased expression of epidermal growth factor receptor (EGFR). Tamoxifen 36-45 epidermal growth factor receptor Homo sapiens 194-198 30140390-0 2018 Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB. Tamoxifen 29-32 epidermal growth factor receptor Homo sapiens 42-46 31821370-6 2019 We found that HIF-induced tamoxifen-resistance involve cross-talk with epithelial growth factor receptor (EGFR), which itself is linked to tamoxifen resistance. Tamoxifen 26-35 epidermal growth factor receptor Homo sapiens 71-104 31821370-6 2019 We found that HIF-induced tamoxifen-resistance involve cross-talk with epithelial growth factor receptor (EGFR), which itself is linked to tamoxifen resistance. Tamoxifen 26-35 epidermal growth factor receptor Homo sapiens 106-110 31821370-6 2019 We found that HIF-induced tamoxifen-resistance involve cross-talk with epithelial growth factor receptor (EGFR), which itself is linked to tamoxifen resistance. Tamoxifen 139-148 epidermal growth factor receptor Homo sapiens 71-104 31821370-6 2019 We found that HIF-induced tamoxifen-resistance involve cross-talk with epithelial growth factor receptor (EGFR), which itself is linked to tamoxifen resistance. Tamoxifen 139-148 epidermal growth factor receptor Homo sapiens 106-110 31670920-14 2019 Tumorigenicity of EGFR and ER+ breast cancer cells were significantly decreased by combined tamoxifen and gefitinib. Tamoxifen 92-101 epidermal growth factor receptor Homo sapiens 18-22 31670920-16 2019 Loss of ER by EGFR activation induced tamoxifen resistance. Tamoxifen 38-47 epidermal growth factor receptor Homo sapiens 14-18 31088266-0 2019 Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway. Tamoxifen 61-64 epidermal growth factor receptor Homo sapiens 73-77 32021441-0 2020 ERalpha36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway. Tamoxifen 48-57 epidermal growth factor receptor Homo sapiens 100-104 30189107-2 2019 Previous studies have documented that PTPH1-associated breast cancers exhibit enhanced sensitivity to tamoxifen and tyrosine kinase inhibitors through dephosphorylation of ER and epidermal growth factor receptor, respectively. Tamoxifen 102-111 epidermal growth factor receptor Homo sapiens 179-211 30050469-6 2018 Evidence that tamoxifen functions as a GPR30 (G-Protein Coupled Receptor 30) agonist activating adenylyl cyclase and EGFR (Epidermal Growth Factor Receptor) intracellular signaling networks, provides yet another means of explaining the multi-functionality of tamoxifen. Tamoxifen 14-23 epidermal growth factor receptor Homo sapiens 117-121 30050469-6 2018 Evidence that tamoxifen functions as a GPR30 (G-Protein Coupled Receptor 30) agonist activating adenylyl cyclase and EGFR (Epidermal Growth Factor Receptor) intracellular signaling networks, provides yet another means of explaining the multi-functionality of tamoxifen. Tamoxifen 14-23 epidermal growth factor receptor Homo sapiens 123-155 30050469-6 2018 Evidence that tamoxifen functions as a GPR30 (G-Protein Coupled Receptor 30) agonist activating adenylyl cyclase and EGFR (Epidermal Growth Factor Receptor) intracellular signaling networks, provides yet another means of explaining the multi-functionality of tamoxifen. Tamoxifen 259-268 epidermal growth factor receptor Homo sapiens 117-121 29028222-0 2018 Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer. Tamoxifen 52-61 epidermal growth factor receptor Homo sapiens 34-38 29484139-0 2018 S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB. Tamoxifen 17-20 epidermal growth factor receptor Homo sapiens 30-34 28100469-12 2017 The numbers of HER2-positive and EGFR-positive cancers were higher in the tamoxifen arm but not significantly so. Tamoxifen 74-83 epidermal growth factor receptor Homo sapiens 33-37 29787277-0 2018 Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. Tamoxifen 119-128 epidermal growth factor receptor Homo sapiens 13-17 29028222-14 2018 Conclusions: RBP2 activates ER-IGF1R-ErbB signaling cascade in multiple ways to induce tamoxifen resistance, suggesting that RBP2 is a potential therapeutic target for ER-driven cancer. Tamoxifen 87-96 epidermal growth factor receptor Homo sapiens 37-41 28786348-5 2018 In considering such a complex network, we speculate that by the time HER2/EGFR is suppressed via targeted therapies, activation of ERalpha66 and ERalpha36 initiate molecular signaling pathways downstream of RTKs, thereby enhancing cell proliferation even in the presence of both Tamoxifen and RTK inhibitors. Tamoxifen 279-288 epidermal growth factor receptor Homo sapiens 74-78 27225751-7 2017 We identified a high EGFR expression in patients who developed distant metastasis or recurrence during tamoxifen treatment (a tamoxifen-resistant group-TR) in contrast to the distant metastasis-free patients (a tamoxifen-sensitive group-TS) (80.0 vs. 41.9 %, respectively, P = 0.009). Tamoxifen 103-112 epidermal growth factor receptor Homo sapiens 21-25 27225751-7 2017 We identified a high EGFR expression in patients who developed distant metastasis or recurrence during tamoxifen treatment (a tamoxifen-resistant group-TR) in contrast to the distant metastasis-free patients (a tamoxifen-sensitive group-TS) (80.0 vs. 41.9 %, respectively, P = 0.009). Tamoxifen 126-135 epidermal growth factor receptor Homo sapiens 21-25 27225751-7 2017 We identified a high EGFR expression in patients who developed distant metastasis or recurrence during tamoxifen treatment (a tamoxifen-resistant group-TR) in contrast to the distant metastasis-free patients (a tamoxifen-sensitive group-TS) (80.0 vs. 41.9 %, respectively, P = 0.009). Tamoxifen 126-135 epidermal growth factor receptor Homo sapiens 21-25 27225751-9 2017 EGFR expression and the distribution pattern of ERalpha expression were associated with the response to tamoxifen by both univariate and multivariate logistic regression analyses. Tamoxifen 104-113 epidermal growth factor receptor Homo sapiens 0-4 27225751-11 2017 Analysis of the distribution pattern of ERalpha expression and the EGFR status in tumor tissue may be valuable for patient selection for tamoxifen adjuvant therapy. Tamoxifen 137-146 epidermal growth factor receptor Homo sapiens 67-71